The potential of bone morphogenetic protein 2 as a neurotrophic factor for Parkinson's disease
Parkinson’s disease is the second most common neurodegenerative disorder; it affects 1% of the population over the age of 65. The number of people with Parkinson’s disease is set to rapidly increase due to changing demographics and there is an unmet clinical need for disease-modifying therapies. The...
Main Authors: | Susan R Goulding, Aideen M Sullivan, Gerard W O'Keeffe, Louise M Collins |
---|---|
Format: | Article |
Language: | English |
Published: |
Wolters Kluwer Medknow Publications
2020-01-01
|
Series: | Neural Regeneration Research |
Subjects: | |
Online Access: | http://www.nrronline.org/article.asp?issn=1673-5374;year=2020;volume=15;issue=8;spage=1432;epage=1436;aulast=Goulding |
Similar Items
-
Growth differentiation factor 5: a neurotrophic factor with neuroprotective potential in Parkinson’s disease
by: Susan R Goulding, et al.
Published: (2022-01-01) -
Neuron-Astrocyte Interactions in Parkinson’s Disease
by: Ikuko Miyazaki, et al.
Published: (2020-12-01) -
Neuroprotective effects of osmotin in Parkinson’s disease-associated pathology via the AdipoR1/MAPK/AMPK/mTOR signaling pathways
by: Jun Sung Park, et al.
Published: (2023-08-01) -
Glutathione S-Transferase Alpha 4 Prevents Dopamine Neurodegeneration in a Rat Alpha-Synuclein Model of Parkinson’s Disease
by: Michael Jewett, et al.
Published: (2018-04-01) -
Mesencephalic astrocyte-derived neurotrophic factor: A treatment option for parkinson’s disease
by: Chun Yang, et al.
Published: (2020-06-01)